

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

## Xeloda (capecitabine)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Xeloda (capecitabine)

### APPROVAL CRITERIA

Requests for Xeloda (capecitabine) may be approved if the following criteria are met:

I. Colon, Rectal or Anal Carcinoma (NCCN 1, NCCN 2A);

**OR**

II. Breast cancer, metastatic or recurrent (label, NCCN 2A);

**OR**

III. Individual has a diagnosis of Central Nervous System Cancers; **AND**

IV. Individual has recurrent disease for brain metastases if active against the primary tumor (breast cancer) (NCCN 2A);

**OR**

V. Head and Neck Cancers, advanced, recurrent, persistent (NCCN 2A);

**OR**

VI. Esophageal and Esophagogastric Cancers (NCCN 1, NCCN 2A);

**OR**

VII. Gastric Cancer (NCCN 1, NCCN 2A);

**OR**

VIII. Recurrent or progressive Gestational Trophoblastic Neoplasia (NCCN 2A);

**OR**

IX. Hepatobiliary Cancers (NCCN 2A);

PAGE 1 of 3 03/28/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0359-19

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

A. Cholangiocarcinoma; **OR**

B. Gallbladder Cancer;

**OR**

X. Neuroendocrine Tumors (NCCN 2A);

A. Gastrointestinal tract, Lung, or Thymus; **OR**

B. Pancreas; **OR**

C. Poorly Differentiated (High Grade)/Large or Small Cell;

**OR**

XI. Occult Primary (NCCN 2A);

**OR**

XII. Ovarian Cancer (NCCN);

**OR**

XIII. Pancreatic Adenocarcinoma (NCCN1, NCCN 2A);

**OR**

XIV. Penile Cancer (NCCN 2A).

**Note:** Xeloda (capecitabine) has a black box warning regarding concomitant use with coumarin-derivative anticoagulants. Concomitant use can alter coagulation parameters that can result in death. Predisposing factors include age greater than 60 and diagnosis of cancer. Individuals should have their INR or prothrombin time monitored frequently in order to have the dose adjusted accordingly.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

PAGE 2 of 3 03/28/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0359-19

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.